Biocon Biologics debuts biosimilar HULIO in US market

In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability of its biosimilar injection, HULIO (adalimumab-fkjp), in the US market.

Already successful in Europe and Canada, HULIO provides an affordable, comparable alternative to the widely-used Humira (adalimumab). This landmark announcement comes shortly after Biocon Biologics’ $3.3 billion acquisition of Viatris’ global biosimilars business, marking another milestone in the company’s mission to offer affordable treatment options in diabetes, cancer, and immunology.

Biocon Biologics’ new addition to the US healthcare market, HULIO, is a testament to the company’s expanding biosimilar product offerings.

Biocon Biologics CEO and Managing Director, Shreehas Tambe, emphasized the company’s commitment to making biologics accessible and affordable, stating, “The launch of HULIO, our biosimilar adalimumab, in the United States is an important milestone for Biocon Biologics as it expands our well-known biosimilar product offering to patients in the United States. This launch builds on our strong presence in oncology and diabetes and re-affirms our commitment to enabling affordable access to biologics.”

Beyond affordability, HULIO is designed with patient-friendly features, including a 2-click, prefilled pen that requires no button pushing.

Mathew Erick, Chief Commercial Officer of Advanced Markets at Biocon Biologics, highlighted the product’s ease of use saying, “Patients remove the cap and push the device against their skin to trigger their injection. Designed and built with patients in mind, healthcare professionals and patients don’t have to miss a beat with HULIO; they simply, ‘Click, Click, Go.'”

In a strategic move to promote accessibility, Biocon Biologics has priced HULIO competitively, offering it at 5% below the current Humira list price, and adalimumab-fkjp at approximately 85% below.

The company also provides HULIO360, a comprehensive patient support program offering benefits verification, prior authorization support, copay assistance, and at-home nurse injection training.

The FDA-approved HULIO is citrate-free and made without natural rubber latex, aligning with standards to reduce hypersensitivity reactions. Post-acquisition of Viatris’ biosimilars portfolio, Biocon Biologics continues to uphold its commitment to accessible healthcare by introducing innovative, patient-friendly solutions like HULIO in the US market.